S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
OTCMKTS:MLLCF

Molecular Partners (MLLCF) Stock Price, News & Analysis

$4.10
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$4.10
$4.10
50-Day Range
$3.91
$4.45
52-Week Range
$3.40
$7.22
Volume
N/A
Average Volume
700 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
MLLCF stock logo

About Molecular Partners Stock (OTCMKTS:MLLCF)

Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317 which is in Phase I clinical trials, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

MLLCF Stock Price History

MLLCF Stock News Headlines

This consistently signaled gains of 453%... 610%... and even 1036%...
It doesn’t happen often, but occasionally, something completely unique comes across my radar. In this case, I’m talking about legal “Insider Trading”. Traders who have consistently signaled 453% … 610% .. and even 1036%... gains. And until now they have been doing it completely under the radar. In an upcoming interview I am revealing the strategy behind this gold-mine and how you can piggy back their every trade.
Molecular Partners AG (MOLN)
Molecular Partners AG ADR (MOLN)
Did You Get Your Free Bitcoin Yet?
And my special guest is willing to give you $10 in Bitcoin (BTC) if you take it seriously. Right now is a very important time to pay attention to what we are doing and what is happening. If you wait... it will be too late. This week we are holding several workshops and if you attend and pay attention my special guest is going to send you $10 in Bitcoin.
Molecular Partners AG (MOLN.SW)
Out of the lab and into the hospital
See More Headlines
Receive MLLCF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
OTCMKTS:MLLCF
CIK
N/A
Fax
N/A
Employees
167
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

  • Dr. Patrick Amstutz Ph.D. (Age 49)
    Co-Founder, CEO, Member of Management Board & Director
    Comp: $745.79k
  • Dr. Michael Tobias Stumpp Ph.D. (Age 52)
    Co-Founder, Executive VP of Projects & Member of Management Board
  • Mr. Robert Hendriks
    Vice President of Finance
  • Mr. Alexander Zurcher (Age 49)
    COO & Member of Management Board
  • Ms. Renate Gloggner (Age 54)
    Executive VP of People & Community and Member of Management Board
  • Mr. Daniel Steiner Ph.D.
    Senior Vice President of Research
  • Mr. Seth D. Lewis
    Senior Vice President of Investor Relations, Communications & Strategy
  • Mr. Michael Pitzner
    General Counsel, Compliance Officer, Senior VP Legal & Business Development
  • Dr. Pamela A. Trail Ph.D. (Age 68)
    Strategic Consultant
  • Ms. Anne Goubier D.V.M.
    Ph.D., Senior Vice President of Biology

MLLCF Stock Analysis - Frequently Asked Questions

How have MLLCF shares performed in 2024?

Molecular Partners' stock was trading at $4.30 at the beginning of 2024. Since then, MLLCF shares have decreased by 4.7% and is now trading at $4.10.
View the best growth stocks for 2024 here
.

How do I buy shares of Molecular Partners?

Shares of MLLCF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (OTCMKTS:MLLCF) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners